A-2021-000129
A-2021-000129 is the reference number for a completed FOI request from the Public Health Agency of Canada (PHAC). It focuses primarily on a series of e-mail communications between PHAC employees in regards to how to handle communications around ivermectin and public requests for its use to treat COVID-19.
Request details
Date | Records Requested | Request No. | Response Letter | Disclosure Package | Notes |
---|---|---|---|---|---|
April 2022 | All communication regarding the use of Ivermectin in the treatment of Covid-19. Date range March 1, 2020 to June 7, 2021. | A-2021-000129 | - | Disclosure | - |
People
The following table outlines the individuals involved in the discussions/materials included in the document release.
Organizations
- Alberta Health Services (AHS)
Therapeutics
Common name | Brand name | Other names | Company | Notes |
---|---|---|---|---|
Anakinra | Kineret | - | Swedish Orphan Biovitrum (Sobi) | - |
Aspirin | - | - | - | - |
Baricitinib | Olumiant | - | Incyte, Eli Lilly | - |
Chloroquine | - | - | - | Not recommended in any context for COVID-19 by Health Canada |
Colchicine | Colcrys, Mitigare, others | - | - | - |
Convalescent plasma | - | - | - | - |
Dexamethasone | - | - | - | - |
Fluvoxamine | - | - | - | - |
Hydroxychloroquine | - | - | - | Not recommended in any context for COVID-19 by Health Canada |
Interferon | - | - | - | Not recommended in any context for COVID-19 by Health Canada |
Ivermectin | Stromectol, Mectizan | - | Merck | Administered intravenously (IV) and orally in studies for the treatment of COVID-19. Authorized by Health Canada for the treatment of parasitic infections in humans and animals. Indicated in humans for the treatment of intestinal strongyloidiasis and onchoceriasis/rosacea. Not recommended for use outside of clinical trials. |
Melatonin | - | - | - | - |
Molnupiravir | - | MK-4482 | Merck, Ridgeback Pharmaceuticals | - |
Lopinavir/ritonavir | Kaletra | - | AbbVie | HIV/AIDS drug |
Quercetin | - | - | - | - |
Remdesivir | Veklury | GS-5734 | Gilead Sciences | - |
Vitamin C | - | Ascorbic acid, ascorbate | - | - |
Vitamin D | - | - | - | |
Zinc | - | - | - | - |
Monoclonal antibodies | ||||
Tixagevimab/cilgavimab | Evushield | AZD7442 | AstraZeneca | - |
Bamlanivimab | - | - | AbCellera, Eli Lilly | - |
Casirivimab and/or imdevimab | - | - | Regeneron, Genentech | - |
Otilimab | - | - | GlaxoSmithKline | - |
Sarilumab | Kevzara | - | Sanofi, Regeneron | - |
Tocilizumab | Actemra | - | Roche | - |
Protocols
Clinical Trials
Trial Number | Name | Sponsor | Principal Investigator |
---|---|---|---|
NCT04527211 | Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel (IveprofCovid19) | Javeriana University | Eduar Echeverri |
NCT04405843 | Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial) | Centro de Estudios en Infectogía Pediatrica | Eduardo López-Medina |
NCT04529525 | Ivermectin to Prevent Hospitalizations in COVID-19 (IVERCORCOVID19) | Instituto de Cardiología de Corrientes | Rodrigo Zoni, Julio Vallejos |
1)
Shared Services Canada. (2020, October 10). Person Information - Adèle Crôteau - Issues Manager - COVID-19 Therapeutics. Government of Canada. https://web.archive.org/web/20221007045418/https://geds-sage.gc.ca/en/GEDS/?pgid=015&dn=Q049QURFTEUuQ1JPVEVBVUBQSEFDLUFTUEMuR0MuQ0EsT1U9REdPLUJERyxPVT1DQ0RJQy1DTENNVEksT1U9SURQQ0ItREdQQ01JLE9VPVBIQUMtQVNQQyxPPUdDLEM9Q0E=
2)
Where Are They Now: Nicole Forbes. (2020, November 20). BioCanRx. https://web.archive.org/web/20230316080334/https://biocanrx.com/now-nicole-forbes
3)
Shared Services Canada. (2020, October 10). Person Information - Niyi Lawuyi - Advisor to Director General. Government of Canada. https://web.archive.org/web/20221007045431/https://geds-sage.gc.ca/en/GEDS/?pgid=015&dn=Q049TklZSS5MQVdVWUlAUEhBQy1BU1BDLkdDLkNBLE9VPURHTy1CREcsT1U9Q0NESUMtQ0xDTVRJLE9VPUlEUENCLURHUENNSSxPVT1QSEFDLUFTUEMsTz1HQyxDPUNB
4)
Celisse Poon Young · Public Health Agency of Canada · Scheduling Assistant. OpenGovCA. Retrieved March 19, 2023, from https://web.archive.org/web/20230319202032/https://opengovca.com/employee/celisse-poon-young